CAJ | 학술논문

目的：观察化纤保肝方治疗气滞血瘀型肝纤维化的疗效。方法：将45例肝纤维化患者随机分为治疗组17例，对照组16例，空白组12例。空白组给予基础保肝治疗：口服硫普罗宁片0.1 g/次，3次/d；治疗组在基础治疗基础上加用化纤保肝方（胶囊剂），4粒/次，3次/d；对照组在此基础上加用扶正化瘀胶囊，5粒/次，3次/d，3组均以治疗12周为1个疗程。1个疗程后观察3组患者治疗前后症状评分的变化，肝功能、肝纤4项、血清转化生长因子β1(TGF-β1)、血小板衍生生长因子(PDGF)、肿瘤坏死因子α(TNF-α)等基因表达以及瞬时弹性检测仪检测的Fibroscan值的变化。结果：治疗组在改善肝纤维化患者的症状、恢复肝功能、降低肝纤4项指标，抑制 TGF-β1、PDGF、TNF-α等基因的表达、降低 Fibroscan 值方面明显优于空白组(P＜0.05)，与对照组比较，差异无统计学意义(P＞0.05)，但明显优于空白组。结论：化纤保肝方具有很好的抗肝纤维化作用。
목적：관찰화섬보간방치료기체혈어형간섬유화적료효。방법：장45례간섬유화환자수궤분위치료조17례，대조조16례，공백조12례。공백조급여기출보간치료：구복류보라저편0.1 g/차，3차/d；치료조재기출치료기출상가용화섬보간방（효낭제），4립/차，3차/d；대조조재차기출상가용부정화어효낭，5립/차，3차/d，3조균이치료12주위1개료정。1개료정후관찰3조환자치료전후증상평분적변화，간공능、간섬4항、혈청전화생장인자β1(TGF-β1)、혈소판연생생장인자(PDGF)、종류배사인자α(TNF-α)등기인표체이급순시탄성검측의검측적Fibroscan치적변화。결과：치료조재개선간섬유화환자적증상、회복간공능、강저간섬4항지표，억제 TGF-β1、PDGF、TNF-α등기인적표체、강저 Fibroscan 치방면명현우우공백조(P＜0.05)，여대조조비교，차이무통계학의의(P＞0.05)，단명현우우공백조。결론：화섬보간방구유흔호적항간섬유화작용。
Objective:To verify clinical effects of HuaQian BaoGan prescription for hepatic fibrosis of Qi sta-ganation and blood stasis pattern. Method:All 45 patients were randomized into 17 cases in the treatment group, 16 cases in the control group and 12 cases in the blank group. The blank group received routine treatment of liver pro-tection;oral tiopronin tablets, each time 0.1g, three times per day;the treatment group took HuaQian BaoGan pre-scription (capsule), four pills each time, three times per day;the control group took FuZheng HuaYu capsule, five pills each time, three times per day. Twelve weeks were one course of treatment. After one course of treatment, the changes of symptom scales before and after treating, liver function index, four indexes of hepatic fibrosis, genetic ex-pressions including transforming growth factorβ1 (TGF-β1), platelet-derived growth factor (PDGF), tumor necrosis factorα (TNF-α) were observed as well as the change of Fibroscan value was detected with instant detector. Result:The treatment group was obviously superior to the blank group in improving the symptoms of patients suffering from hepatic fibrosis, liver function recovery, decreasing four indexes of hepatic fibrosis, inhibiting genetic expressions in-cluding TGF-β1, PDGF, TNF-α and others, lowering Fibroscan value (P<0.05), the difference had no statistical meaning compared with the control group(P>0.05), but obviously better than the blank group. Conclusion:HuaQian BaoGan prescription shows better effects against hepatic fibrosis.